glp-1 obesity drug news today september 29 2025 Weight-Loss Demonstration Begins July 2026 GLP-1 trends 2025: real-world data,

The statistical difference between the two groups (p=0.002) provides strong evidence for our conclusions

The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear

Any misuse or off-label application is strictly prohibited.

When evaluating the quality of the 18 articles 2 , 6 , 11 - 26 selected through the Jadad Scale, their scores ranged between 2 and 5, with a median score of 5 (Table 1)